ClinicalTrials.gg
CompletedNCT05619744Updated Mar 10, 2025

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

A Phase 1 interventional study of RO7616789 and Tocilizumab in Small Cell Lung Cancer and Neuroendocrine Carcinoma, sponsored by Hoffmann-La Roche. Completed at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Hoffmann-La Roche.

Enrollment
11th of 14
41 · median 123
Started
2023
the only one that year
Phase 1
5 of 16
1 open now
Registered
15th of 16
by date

Among the 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, and was the 15th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

1 of the 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study.

03

Conditions studied

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 12 weeks
  • (ECOG) performance status of 0 or 1
  • Adequate hematologic and end organ function
  • Negative serum pregnancy test.
  • Adequate and no or interruption of breastfeeding
  • confirmed extensive SCLC or poorly differentiated NEC of any other origin, after at least 1 systemic therapy
  • according to (RECIST) Version 1.1
  • Confirmed availability of representative in formalin-fixed, paraffin-embedded (FFPE) blocks or unstained slides

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 40 days after the final dose of study treatment
  • Poorly controlled Type 2 diabetes mellitus defined as a screening ≥ 8% or a fasting plasma glucose ≥ 160 mg/dL (or 8.8 mmol/L)
  • corrected using Fridericia's formula (QTcF) > 470 ms. Abnormal (ECGs) (triplicate) should be performed > 30 minutes apart
  • Current treatment with medications that are well known to prolong the QT interval
  • Prior treatment with anti-cluster of differentiation (CD)137 agents, anti-CD3 agents and/or delta-like ligand 3 (DLL3) targeted therapies
  • Any anti-cancer therapy, whether or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 21 days prior to initiation of study treatment
  • Any history of an immune-related Grade 4 adverse event (AE) attributed to prior anti-programmed death ligand-1 () /PD-1 or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) therapy (other than asymptomatic elevation of serum amylase or lipase)
  • Any history of an immune-related Grade 3 adverse event attributed to prior anti-PD-L1 /PD-1 or anti-CTLA-4 therapy (other than asymptomatic elevation of serum amylase or lipase) that resulted in permanent discontinuation of the prior immunotherapeutic agent
  • History or clinical evidence of primary central nervous system (CNS) , symptomatic , CNS metastases requiring any anti-tumor treatment, or and current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • Spinal cord compression that has not been definitively treated with surgery and/or radiation
  • Active or history of disease
  • Positive test for (HIV) infection
  • Positive surface antigen (HbsAg) test, and/or positive total hepatitis B core antibody (HbcAb) test at screening
  • Prior hematopoietic stem cell transplantation or prior solid organ transplantation
  • Administration of a live, attenuated vaccine within 4 weeks before first RO7616789 infusion
  • Known allergy or to any component of the RO7616789 formulation
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Part 1: RO7616789 QW: Dose Escalation

    Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.

    Drug: RO7616789 · Drug: Tocilizumab

  • Experimental
    Part 2: RO7616789 Q3W: Dose Escalation

    Participants will receive a fixed dose of RO7616789, at a dose determined in Part 1, intravenously once every 3 weeks (Q3W) on Day 1 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.

    Drug: RO7616789 · Drug: Tocilizumab

  • Experimental
    Part 3: Dose Expansion

    Based on emerging data from Part 1 and 2, one or more dosing regimens will be further investigated in Part 3.

    Drug: RO7616789 · Drug: Tocilizumab

Interventions

  • DrugRO7616789

    RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.

  • Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.

    Also known as: Actemra, RoActemra

06

What researchers measure

Primary outcomes

  1. Part 1, 2 and 3: Number of Participants with Adverse Events and Serious Adverse Events

    Adverse events were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), and Cytokine release syndrome (CRS), will be graded based on the American Society for Transplantation and Cell Therapy (ASTCT) criteria.

    Time frame: Up to approximately 26 months

  2. Part 1 and 2: Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: Day 1 through Day 21 in cycle 1 (Cycle is 21 days)

  3. Part 3: Objective Response Rate (ORR) as determined by Investigator

    Time frame: Up to approximately 26 months

  4. Part 3: Disease Control Rates as Determined by the Investigator

    Time frame: Up to approximately 26 months

  5. Part 3: Duration of Response (DOR) as Determined by the Investigator

    Time frame: Up to approximately 26 months

  6. Part 3: Progression Free Survival (PFS) as Determined by the Investigator

    Time frame: Up to approximately 26 months

  7. Part 3: Overall Survival (OS)

    Time frame: Up to approximately 26 months

Secondary outcomes

  1. Part 1, 2 and 3: Serum Concentration of RO7616789

    Time frame: Up to approximately 26 months

  2. Part 1, 2 and 3: Maximum Serum Concentration (Cmax) of RO7616789

    Time frame: Up to approximately 26 months

  3. Part 1, 2 and 3: Area Under the Concentration-Time Curve (AUC) of RO7616789

    Time frame: Up to approximately 26 months

  4. Part 1, 2 and 3: Total Clearance of RO7616789

    Time frame: Up to approximately 26 months

  5. Part 1, 2 and 3: Terminal Half-Life of RO7616789

    Time frame: Up to approximately 26 months

  6. Part 1, 2 and 3: Volume of Distribution of RO7616789

    Time frame: Up to approximately 26 months

  7. Part 1, 2 and 3: Time to Reach Steady State Concentration of RO7616789

    Time frame: Up to approximately 26 months

  8. Part 1, 2 and 3: Accumulation Ratio of RO7616789

    Time frame: Up to approximately 26 months

  9. Part 1 and 2: ORR as Determined by the Investigators

    Time frame: Up to approximately 26 months

  10. Part 1 and 2: Disease Control Rates as Determined by the Investigator

    Time frame: Up to approximately 26 months

  11. Part 1 and 2: DOR as Determined by the Investigators

    Time frame: Up to approximately 26 months

  12. Part 1 and 2: PFS as Determined by the Investigators

    Time frame: Up to approximately 26 months

  13. Part 1 and 2: OS as Determined by the Investigators

    Time frame: Up to approximately 26 months

  14. Part 1, 2 and 3: Percentage of Participants With Anti-Drug Antibody (ADA) to RO7616789

    Time frame: Up to approximately 26 months

07

Study locations

17 sites
  • Georgetown Uni Medical Center
    Washington, District of Columbia 20007, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2689, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Rigshospitalet
    København Ø, 2100, Denmark
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • Uniwersyteckie Centrum Kliniczne
    Gda?sk, 80-214, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2025, 25 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 25 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 17, 2022
StartActual
Jan 23, 2023
Primary completionActual
Mar 4, 2025
CompletionActual
Mar 4, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05619744
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Jan 23, 2023
Primary completion
Mar 4, 2025
Completion
Mar 4, 2025
Last update
Mar 10, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion